Otsuka Pharmaceutical Co., Ltd.
H. Lundbeck A/S

Pharmaceuticals

January 8, 2019

Selincro (nalmefene) Tablets 10mg Receives Regulatory Approval in Japan

First Drug Approved in Japan to Reduce Alcohol Consumption in Alcohol-dependent Patients

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A / S of Denmark are pleased to announce that Otsuka has received regulatory approval in Japan for the manufacture and sale of Selincro Tablets 10 mg (generic name: nalmefene hydrochloride), a therapeutic drug treatment to reduce alcohol consumption in alcohol-dependent patients.

In 2013 Otsuka formed an agreement with Lundbeck on the development and commercialization in Japan of Lundbeck's nalmefene.

Latest Pharmaceutical Business related News Releases

17 APR 2023

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia

30 JAN 2023

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan

10 JAN 2023

Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

Most Recent Releases

Otsuka Pharmaceutical Co., Ltd. H. Lundbeck A/S

Selincro (nalmefene) Tablets 10mg Receives Regulatory Approval in Japan

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti® (brexpiprazole) in Japan

Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

Otsuka Pharmaceutical Co., Ltd.
H. Lundbeck A/S

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan